IL10 and neoplasm: For example, tumor-derived IL-10 and TGF-β drive DCs into a tolerogenic state, reducing MHC-II and co-stimulatory molecule expression while upregulating inhibitory ligands (e.g. PD-L1), which together impair effector T cell priming (10).